Indeed, the lytic capacity of the CD8+ T cells appeared relatively robust to the influence of indisulam up to a concentration of 2.5 μM, with only marginal effects at 10 μM, and even following treatment with 40 μM indisulam, the antigen-specific T cells (Tcellsgp100) were still able to kill the antigen-positive tumor cells. This evidence concerns the gene CD8A and neoplasm.